Natco Pharma announced today that it is the first company in India to launch a generic version of Teriflunomide, for the treatment of Relapsing and Remitting forms of Multiple Sclerosis (RRMS), under its brand DENOPSY.

This is the first oral medicine for RRMS being offered in India at two different strengths- 14 mg & 7 mg tablets. Teriflunomide is sold by Sanofi-Genzyme under brand name of AUBAGIO®, in the USA market.
 
DENOPSY is priced attractively & much lower than other alternate options in India. As per WHO 2013 estimates, the number of patients suffering from Multiple Sclerosis in India is 5-20 per 1 lakh population.

Shares of the company declined Rs 11.25, or 1.45%, to settle at Rs 765.00. The total volume of shares traded was 39,502 at the BSE (Wednesday).